Companies:

 

Articles:

 
Hot Topics

Trump’s CBD Comments Ignite US Cannabis Stocks Surge – Will ASX Companies Follow Suit?

Go to Paul Sanger author's page
By Paul Sanger - 
Trump CBD Comments Ignite US Cannabis Stocks Surge
Copied

Shares of cannabis and CBD-related companies surged on Monday after US President Donald Trump posted on Truth Social that hemp-derived cannabidiol (CBD), especially in senior healthcare,  “could revolutionize” treatment by reducing disease progression and providing an alternative to prescription drugs.

He further reiterated his administration is exploring reclassifying marijuana under federal law, a change that could ease criminal penalties and open broader market access.

The market reacted strongly: Tilray Brands (TLRY) jumped ~42%, Canopy Growth (WEED) rose ~18%, Cronos Group ~15.5%, and Aurora Cannabis ~25%, while cannabis-focused ETFs like MSOS and Roundhill climbed ~21% each, on hopes of a paradigm shift in regulatory treatment for CBD / cannabis equities.

Why This Matters for ASX Cannabis / Hemp / CBD Stocks

Although the regulatory environment in Australia is different – full recreational legalisation remains off the table, and cannabis is tightly regulated – the US is often a bellwether for sentiment and capital flows in the broader cannabis sector.

Here are a few ways ASX cannabis/ CBD / hemp stocks might benefit:

Sentiment & Capital Flow Spillover

  • A positive regulatory shift in the US could drive investor interest in the entire cannabis space globally, including Australia.
  • ASX-listed CBD / hemp companies might see increased inflows from global funds looking to play the sector.

Licensing & Export Opportunities

  • Australia already allows medicinal cannabis, and some companies are working on hemp and CBD products.
  • If US regulatory risk diminishes, Australian producers could find more partners or export markets, especially for hemp/CBD derivatives.

Valuation Re-rating and M&A Interest

  • ASX CBD / hemp stocks may see re-ratings as multiples expand due to a more favourable US outlook.
  • International cannabis / hemp players could look to acquire or partner with Australian companies to access unique assets or regulatory arbitrage.

Technology and Research Cross-Over

  • Many Australian cannabis / biotech firms focus on medical / therapeutic cannabis, cannabinoid formulations, or derivative products.
  • In a more permissive US regime, their research / IP could gain more global relevance and licensing potential.

ASX Cannabis / Hemp Stocks to Watch

Little Green Pharma (ASX: LGP) — One of the first movers in Australia’s medicinal cannabis industry, with established cultivation and production facilities. LGP has also secured exports into Europe, giving it international reach that could benefit from shifting US sentiment around cannabis.

Botanix Pharmaceuticals (ASX: BOT) — Focused on cannabinoid-based dermatological therapies.

Vitura Health (ASX: VIT) — Involved in CBD / medicinal cannabis distribution and digital health platforms.

Cann Group (ASX: CAN) — A more traditional medical cannabis operator in Australia; its valuation could see relief from a more globally friendly cannabis outlook.